SCHEMBL3972401

SCHEMBL3972401

Cc1oc(Br)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.52
MAPT P10636 2/20 0.52
APEX1 P27695 3/20 0.49
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
GLA P06280 1/20 0.47
GPR35 Q9HC97 4/20 0.43
HSD17B10 Q99714 4/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
POLB P06746 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1598651 0.78 ALDH1A1 (0.46) MAPTHSD17B10ALDH1A1KDM4EPOLB
SCHEMBL546834 0.77 MAPT (0.59) TTRMAPTAPEX1NPC1RAB9A
Hydrochloric Acid SCHEMBL3043164 0.76 MAPT (0.57) TTRMAPTAPEX1NPC1RAB9A
SCHEMBL8978501 0.76 GPR35 (0.44) GLAGPR35HSD17B10KDM4ESMN1; SMN2
SCHEMBL8630653 0.74 TTR (0.57) TTRMAPTAPEX1NPC1RAB9A
SCHEMBL31619086 0.74 TTR (0.66) TTRMAPTAPEX1NPC1RAB9A
SCHEMBL11718003 0.72 MAPT (0.50) TTRMAPTAPEX1NPC1RAB9A
SCHEMBL11722067 0.71 TTR (0.68) TTRMAPTAPEX1NPC1RAB9A
SCHEMBL3907975 0.71 TTR (0.58) TTRMAPTAPEX1NPC1RAB9A
SCHEMBL10715763 0.71 PIM1 (0.36) MAPTAPEX1NPC1RAB9AGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317708-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-09-26 US disclosed
EP-4192812-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-09-04 EP disclosed
CN-117561240-A Inhibitors of transglutaminase 策迪拉有限公司 2024-02-13 CN disclosed
EP-4192812-A1 INHIBITORS OF TRANSGLUTAMINASES Zedira GmbH (DE) 2023-06-14 EP disclosed
US-20230124700-A1 OXAZOLE AND THIOAZOLE-TYPE CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2023-04-20 US disclosed
WO-2023275333-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 WO disclosed
EP-4045142-A1 OXAZOLE AND THIOAZOLE-TYPE CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) 2022-08-24 EP disclosed
WO-2021074414-A1 OXAZOLE AND THIOAZOLE-TYPE CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2021-04-22 WO disclosed
WO-2021074414-A1 OXAZOLE AND THIOAZOLE-TYPE CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2021-04-22 WO disclosed
EP-1732882-B1 NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS REVOTAR BIOPHARMACEUTICALS AG (DE) 2012-07-04 EP disclosed
WO-2005037812-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2005-04-28 WO disclosed
US-4945177-A Antimicrobially active nitriles and the production thereof HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1990-07-31 US disclosed
US-4728743-A Process for the production of 3-oxonitriles DEGUSSA AKTIENGESELLSCHAFT (DE) 1988-03-01 US disclosed
US-4716237-A Process for the production of 3-oxonitriles DEGUSSA AKTIENGESELLSCHAFT (DE) 1987-12-29 US disclosed
EP-0220250-A1 UTILIZATION OF NITRILES AS ANTIMICROBIAL AGENTS Henkel Kommanditgesellschaft auf Aktien (DE) 1987-05-06 EP disclosed
EP-0220220-A1 Process of preparing 2,2-dibromo-3-oxonitriles. HENKEL KGAA (DE) 1987-05-06 EP disclosed
WO-1986006254-A1 UTILIZATION OF NITRILES AS ANTIMICROBIAL AGENTS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1986-11-06 WO disclosed
WO-1986006369-A1 ANTI-MICROBIAL NITRILE AND ITS PRODUCTION HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1986-11-06 WO disclosed
EP-0089011-B1 PROCESS FOR THE PREPARATION OF 5-OXONITRILES Degussa Aktiengesellschaft (DE) 1985-07-10 EP disclosed
EP-0089011-A1 Process for the preparation of 5-oxonitriles Degussa Aktiengesellschaft (DE) 1983-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124700-A1 OXAZOLE AND THIOAZOLE-TYPE CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF CUL1, CUL5, CUL3 TTR 2116/4885MAPT 560/4885APEX1 1820/4885
US-20240317708-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 TTR 682/4885MAPT 989/4885APEX1 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.